We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
- Authors
Prokopchuk, Olga; Grünwald, Barbara; Nitsche, Ulrich; Jäger, Carsten; Prokopchuk, Oleksii L.; Schubert, Elaine C.; Friess, Helmut; Martignoni, Marc E.; Krüger, Achim; Grünwald, Barbara; Jäger, Carsten; Krüger, Achim
- Abstract
<bold>Background: </bold>Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a candidate diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). Here, we determined the possible association of systemic TIMP-1 levels with cachexia and jaundice, two common PDAC-associated conditions.<bold>Methods: </bold>Plasma TIMP-1 was measured by ELISA in patients diagnosed with PDAC (n = 36) and chronic pancreatitis (CP) (n = 25). Patients without pancreatic pathologies and known malignancies of other origin served as controls (n = 13). TIMP-1 levels in these patients were tested for asscociation with jaundice and chachexia, and furthermore correlated with cachexia-related clinical parameters such as weight loss and ferritin, parameters of lung function, hemoglobin and liver synthesis parameters.<bold>Results: </bold>TIMP-1 plasma levels were mostly higher in CP and PDAC patients with concomitant jaundice or cachexia. Elevated plasma TIMP-1 levels were also associated with clinical cachexia markers, including absolute and relative values of weight loss and lung function, as well as ferritin, hemoglobin, and cholinesterase levels. TIMP-1 levels significantly correlated with cachexia only in patients without jaundice. Jaundice also impaired the use of TIMP-1 as a prognostic marker in cancer patients. Relating to cachexia status alone, a slightly improved association of TIMP-1 levels with survival of PDAC patients was observed.<bold>Conclusion: </bold>This retrospective study reports for the first time that plasma levels of TIMP-1 are associated with pancreatic lesion-induced cachexia in patients without jaundice. TIMP-1 is counterindicated as a survival marker in patients with jaundice.
- Subjects
MATRIX metalloproteinase inhibitors; TISSUE inhibitors of metalloproteinases; CACHEXIA; PANCREATIC cancer; PANCREATITIS; JAUNDICE; PATIENTS; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; PANCREATIC tumors; PROTEINS; RESEARCH; RESEARCH funding; EVALUATION research; RETROSPECTIVE studies; ACUTE diseases; DUCTAL carcinoma; DISEASE complications
- Publication
BMC Cancer, 2018, Vol 18, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-018-4055-9